Carboplatin
Induction of metallothionein expression by supplementation of zinc induces resistance against platinum-based treatment in malignant pleural mesothelioma
Translational Cancer Research 2023 August 31 [Link] Martine Wyrich, Henning Ohlig, Michael Wessolly, Elena Mairinger, Julia Steinborn, Luka Brcic, Balazs Hegedus, Thomas Hager, Kristina Greimelmaier, Jeremias Wohlschlaeger, Fabian D Mairinger, Sabrina Borchert Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive tumor with a dismal prognosis. Currently, multimodality treatment including chemotherapy with cisplatin or carboplatin…
Read MoreCost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland
Pharmacoeconomics 2023 August 12 [Link] Michaela Carla Barbier, Alicia Fengler, Esther Pardo, Arjun Bhadhuri, Niklaus Meier, Oliver Gautschi Abstract Background: Malignant pleural mesotheliomas (MPMs) are aggressive and often unresectable. In the past, chemotherapy was the standard for palliative treatment. However, immunotherapy with nivolumab+ipilimumab has recently received marketing approval. Objectives: This study evaluated the cost effectiveness…
Read MoreUnusually Aggressive Presentation of Malignant Peritoneal Mesothelioma: Two Case Reports
Case Reports in Oncology 2022 November 8 [Link] Dominik Neff, Barbara-Christina Padberg Sgier, Hannah Dietze, Joachim Müller, Martin Früh Abstract Malignant peritoneal mesothelioma is a rare disease. Patients mainly present with abdominal distension, pain, nausea, and weight loss with or without an exposure history of asbestos. Diagnosis may be difficult from a clinical and histopathologic…
Read MoreManagement of Advanced Pleural Mesothelioma-At the Crossroads
JCO Oncology Practice 2021 September 7 [Link] Anna K Nowak, Alannah Jackson, Calvin Sidhu Abstract The management of pleural mesothelioma has changed with the demonstration that first-line checkpoint blockade therapy improves survival. This review covers issues of relevance to the practicing medical oncologist, with an emphasis on the palliative setting and on new information. Until…
Read MoreMalignant mesothelioma without asbestos exposure diagnosed during EGFR-TKI treatment of lung adenocarcinoma: A case report
Cancer Treatment and Research Communications 2021 February 24 [Link] Xiaomin Niu, Chenglei Zhou, Aiyan Hu, Lingzi Su, Dan Lin, Hui Han, Yan Lu Abstract Synchronous malignant mesothelioma (MM) and lung carcinoma are extremely rare in patients without a history of asbestos exposure and poses tremendous difficulties in clinical management. We report a patient without asbestos…
Read MoreFirst-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Lancet 2021 January 21 [Link] Paul Baas, Arnaud Scherpereel, Anna K Nowak, Nobukazu Fujimoto, Solange Peters, Anne S Tsao, Aaron S Mansfield, Sanjay Popat, Thierry Jahan, Scott Antonia, Youssef Oulkhouir, Yolanda Bautista, Robin Cornelissen, Laurent Greillier, Francesco Grossi, Dariusz Kowalski, Jerónimo Rodríguez-Cid, Praveen Aanur, Abderrahim Oukessou, Christine Baudelet, Gérard Zalcman Abstract Background: Approved systemic treatments…
Read MoreThe Impact on Outcome by Adding Bevacizumab to Standard Induction Chemotherapy Prior to Mesothelioma Surgery: A Retrospective Single Center Analysis
Frontiers in Oncology 2020 November 13 [Link] Olivia Lauk, Karina Bruestle, Thomas Neuer, Bianca Battilana, Thi Dan Linh Nguyen, Thomas Frauenfelder, Rolf Stahel, Walter Weder, Alessandra Curioni-Fontecedro, Isabelle Opitz Abstract Objectives: Adding bevacizumab, an anti-Vascular Endothelial Growth Factor (VEGF), to platinum-based chemotherapy/pemetrexed in 1st line treatment of advanced malignant pleural mesothelioma (MPM), significantly improved overall…
Read MoreDurvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in
The Lancet Oncology 2020 September [Link] Anna K Nowak, W Joost Lesterhuis, Peey-Sei Kok, Chris Brown, Brett Gm Hughes, Deme J Karikios, Thomas John, Steven C-H Kao, Connull Leslie, Alistair M Cook, Nick Pavlakis, Karen Briscoe, Kenneth J O’Byrne, Christos S Karapetis, Wei-Sen Lam, Ailsa Langford, Sonia Yip, Martin R Stockler Abstract Background: There is…
Read MoreRandomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901
Clinical Lung Cancer 2020 July 3 [Link] Arkadiusz Z Dudek, Xiaofei Wang, Lin Gu, Stephanie Duong, Thomas E Stinchcombe, Robert Kratzke, Hossein Borghaei, Everett E Vokes, Hedy L Kindler Abstract Background: The role of maintenance therapy for malignant pleural mesothelioma (MPM) is unknown. We performed a randomized phase II trial to determine if continuation of…
Read MoreImpressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.
Lung Cancer 2020 February 14 [Link] Bronte G, Delmonte A, Burgio MA, Verlicchi A, Puccetti M, Bravaccini S, Cravero P, Tumedei MM, Diano D, Rossi G, Ulivi P, Martinelli G, Crinò L Abstract OBJECTIVES: Treatment options for malignant pleural mesothelioma (MPM) are limited but some studies on immune checkpoint inhibitors (ICIs) in MPM have reported…
Read More